LifeVantage Corporation

NasdaqCM:LFVN 株式レポート

時価総額：US$65.2m

LifeVantage 将来の成長

Future 基準チェック /06

LifeVantageの収益と利益はそれぞれ年間6.4%と10.7%減少すると予測されていますが、EPS は年間10.8% 減少すると予測されています。

主要情報

-10.7%

収益成長率

-10.81%

EPS成長率

Personal Products 収益成長33.1%
収益成長率-6.4%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日13 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • May 01

LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential

Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.
ナラティブの更新 • Apr 17

LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential

Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.
ナラティブの更新 • Apr 02

LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential

Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.
ナラティブの更新 • Mar 19

LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential

Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.
ナラティブの更新 • Mar 05

LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential

Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.
ナラティブの更新 • Feb 18

LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential

Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.
分析記事 • Feb 06

Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding

Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...
ナラティブの更新 • Feb 04

LFVN: Gut Health Research Progress Will Support Confident Upside Potential

Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).
ナラティブの更新 • Jan 21

LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential

Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).
ナラティブの更新 • Jan 07

LFVN: Gut Study Progress Will Drive Future Upside Potential

Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).
ナラティブの更新 • Dec 22

LFVN: Future Gut Health Research And Buybacks Will Drive Upside

Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.
ナラティブの更新 • Dec 08

LFVN: Future Index Inclusion Will Drive Upside Potential

Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).
ナラティブの更新 • Nov 24

LFVN: Share Repurchases and New Index Addition Will Drive Value

LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.
分析記事 • Nov 14

Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop

Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...
分析記事 • Nov 04

We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
分析記事 • Sep 30

It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks

LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...
分析記事 • Sep 05

LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045

The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...
Seeking Alpha • Jul 21

The LifeVantage Advantage: High Retention, High Returns

Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking Alpha
分析記事 • May 13

Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality

When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...
分析記事 • May 02

What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash

To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...
User avatar
新しいナラティブ • Feb 14

New Initiatives Will Drive MindBody GLP-1 System's Future Success

Expansion into international markets and enhanced supply chain capacity are expected to drive significant revenue growth and stabilize future sales.
分析記事 • Feb 09

LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.04

LifeVantage Corporation's ( NASDAQ:LFVN ) investors are due to receive a payment of $0.04 per share on 17th of March...
分析記事 • Feb 07

LifeVantage Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's been a mediocre week for LifeVantage Corporation ( NASDAQ:LFVN ) shareholders, with the stock dropping 10% to...
Seeking Alpha • Feb 06

LifeVantage: Post-Earnings Sell-Off Provides Buying Opportunity

Summary LifeVantage Corporation's Q2 FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%. While the current expense headwinds are expected to abate going into FY2026, I have lowered Adjusted EBITDA estimates and reduced my price target from $31 to $27. While investor disappointment is understandable, I consider the post-earnings sell-off a buying opportunity. That said, with the story being largely tied to the persistent success of a single blockbuster product, the investment thesis is not without risks. Read the full article on Seeking Alpha
分析記事 • Feb 05

LifeVantage Corporation (NASDAQ:LFVN) Looks Just Right With A 33% Price Jump

Despite an already strong run, LifeVantage Corporation ( NASDAQ:LFVN ) shares have been powering on, with a gain of 33...
分析記事 • Feb 01

What Is LifeVantage Corporation's (NASDAQ:LFVN) Share Price Doing?

LifeVantage Corporation ( NASDAQ:LFVN ), is not the largest company out there, but it led the NASDAQCM gainers with a...
分析記事 • Dec 20

Market Participants Recognise LifeVantage Corporation's (NASDAQ:LFVN) Earnings Pushing Shares 31% Higher

LifeVantage Corporation ( NASDAQ:LFVN ) shares have continued their recent momentum with a 31% gain in the last month...
分析記事 • Dec 16

LifeVantage (NASDAQ:LFVN) Will Be Hoping To Turn Its Returns On Capital Around

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...

業績と収益の成長予測

NasdaqCM:LFVN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
6/30/20281654N/AN/A1
6/30/2027178511163
6/30/202618457153
3/31/2026195647N/A
12/31/2025210824N/A
9/30/202522910910N/A
6/30/2025229101112N/A
3/31/202522291213N/A
12/31/202421271314N/A
9/30/2024196457N/A
6/30/202420031012N/A
3/31/202420541113N/A
12/31/202321131114N/A
9/30/20232133913N/A
6/30/2023213347N/A
3/31/2023210-136N/A
12/31/2022206-113N/A
9/30/2022205046N/A
6/30/2022206368N/A
3/31/202221091214N/A
12/31/2021212101316N/A
9/30/2021219141518N/A
6/30/2021220131316N/A
3/31/2021225121317N/A
12/31/2020229121517N/A
9/30/2020232121821N/A
6/30/2020233121618N/A
3/31/2020230121316N/A
12/31/201923012N/A17N/A
9/30/20192278N/A12N/A
6/30/20192267N/A18N/A
3/31/20192247N/A16N/A
12/31/20182186N/A16N/A
9/30/20182106N/A13N/A
6/30/20182036N/A13N/A
3/31/20182003N/A10N/A
12/31/20171941N/A6N/A
9/30/20171941N/A6N/A
6/30/20171992N/A7N/A
3/31/20172024N/A4N/A
12/31/20162135N/A3N/A
9/30/20162166N/A6N/A
6/30/20162076N/A6N/A
3/31/20161994N/A10N/A
12/31/20151883N/A14N/A
9/30/20151843N/A11N/A
6/30/20151907N/A13N/A

アナリストによる今後の成長予測

収入対貯蓄率: LFVNの収益は今後 3 年間で減少すると予測されています (年間-10.7% )。

収益対市場: LFVNの収益は今後 3 年間で減少すると予測されています (年間-10.7% )。

高成長収益: LFVNの収益は今後 3 年間で減少すると予測されています。

収益対市場: LFVNの収益は今後 3 年間で減少すると予想されています (年間-6.4% )。

高い収益成長: LFVNの収益は今後 3 年間で減少すると予測されています (年間-6.4% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LFVNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/18 12:10
終値2026/05/15 00:00
収益2026/03/31
年間収益2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

LifeVantage Corporation 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Ilya ZubkovFreedom Broker
Mitchell PinheiroImperial Capital
Ryan MeyersLake Street Capital Markets, LLC